儿童非典型神经炎症的诊断与管理
本文综述了既无诊断性自身抗体、也不符合特定临床病理实体标准的儿童神经免疫疾病,包括血清阴性自身免疫性脑炎、血清阴性脱髓鞘疾病及免疫失调或继发性神经炎症的遗传病。建议进行广泛诊断性检查以支持神经炎症、排除非神经免疫疾病、检测自身抗体及生物标志物、识别潜在遗传驱动因素,并提出诊断管理算法。一线急性治疗以激素开始,可考虑血浆置换或IVIG;二线或维持治疗需根据疑似机制和复发可能性选择。
要点
- 对非典型儿童神经免疫疾病应广泛鉴别CNS感染、非炎性遗传病、毒物暴露、代谢紊乱及原发性精神障碍。
- 一线急性治疗以激素开始,可考虑血浆置换或IVIG。
- 二线或维持治疗选择困难,可基于疑似神经炎症机制和复发可能性考虑免疫治疗。
核心结论
- 对于非典型血清阴性儿童神经免疫疾病,建议广泛诊断性检查以支持神经炎症、排除非神经免疫疾病、检测自身抗体及生物标志物、识别潜在遗传驱动因素,并提供病例特异性病理生理机制见解。
研究设计与样本
- 综述,未报告检索范围。
主要发现
- 非典型儿童神经免疫疾病包括血清阴性自身免疫性脑炎、血清阴性脱髓鞘疾病如NMOSD,以及免疫失调或继发性神经炎症的遗传病。
- 这些病例的广泛鉴别诊断应包括CNS感染、非炎性遗传病、毒物暴露、代谢紊乱和原发性精神障碍。
关键数值与推荐
- 一线急性治疗以激素开始,可考虑血浆置换或IVIG。
- 二线或维持治疗选择困难,无明确特定诊断及已确立的循证治疗选项。
- 基于疑似机制可考虑免疫治疗:可能抗体介导或B细胞介导炎症可考虑利妥昔单抗;某些细胞因子介导炎症或先天免疫系统失调可考虑抗IL-6药物、抗IL-1药物或JAK抑制剂。
临床怎么用
- 监测治疗反应和疾病活动,遇到意外发现或治疗反应不佳时重新审视鉴别诊断,权衡免疫治疗风险与经验性治疗获益。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pediatric neuroimmune disorders comprise a heterogeneous group of immune-mediated CNS inflammatory conditions. Some, such as multiple sclerosis, are well defined by validated diagnostic criteria. Others, such as anti-NMDA receptor encephalitis, can be diagnosed with detection of specific autoantibodies. This review addresses neuroimmune disorders that neither feature a diagnosis-defining autoantibody nor meet criteria for a distinct clinicopathologic entity. A broad differential in these cases should include CNS infection, noninflammatory genetic disorders, toxic exposures, metabolic disturbances, and primary psychiatric disorders. Neuroimmune considerations addressed in this review include seronegative autoimmune encephalitis, seronegative demyelinating disorders such as neuromyelitis optica spectrum disorder, and genetic disorders of immune dysregulation or secondary neuroinflammation. In such cases, we recommend a broad diagnostic workup to support the presence of neuroinflammation, exclude non-neuroimmune disorders, detect autoantibodies and other biomarkers of known diseases, identify any potential genetic drivers of neuroinflammation, and provide case-specific insights into pathophysiologic mechanisms of inappropriate immune pathway activation or dysregulation. This review includes an extensive list of useful diagnostic tests and potential implications thereof, as well as a proposed algorithm for the diagnosis and management of the pediatric patient with atypical neuroimmune disorders. In general, first-line acute treatment of neuroimmune disorders begins with steroids, along with consideration of plasmapheresis or IV immunoglobulin. Selection of second-line or maintenance therapy is challenging without a definite, specific diagnosis and the associated benefit of established evidence-based treatment options. Immunotherapies may be considered based on the suspected mechanism of neuroinflammation and the likelihood of relapse. For example, rituximab may be considered for possible antibody-mediated or B-cell-mediated inflammation while anti-interleukin (IL)-6 agents, anti-IL-1 agents, or JAK inhibitors may be considered for certain cases of cytokine-mediated inflammation or innate immune system dysregulation. Care should be taken to monitor response and disease activity, revisit the differential diagnosis in the case of unexpected findings or poor treatment response, and weigh the risks of immunotherapy with the benefits of empiric treatment. Over time, further advancements in biomarker identification and omics research may define specific new clinicopathologic diagnoses and thus obviate the need for "n of 1" approaches to what are currently heterogeneous groups of atypical seronegative neuroimmune disorders.
引用
- Saucier L, Rossor T, Gorman MP, et al. Diagnosis and Management of Children With Atypical Neuroinflammation. Neurology. 2025. PMID: 40184590. doi:10.1212/WNL.0000000000213537
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。